Lei Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Qin has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Zecai Chen
8 shared publicationsZhen Xu
7 shared publicationsDazhi Yang
6 shared publications- Guozhi Xiao
Department of Biochemistry, Homeostatic Medicine Institute, School of Medicine, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment, Southern University of Science and Technology, Shenzhen, 518055, China
6 shared publications Weihong Yi
6 shared publications- Weihong Yi
Department of Orthopedics, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518000, China
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 64, 641-654
Spatiotemporal regulation of neutrophil-mediated immune cascades via engineered PEEK surfaces restores osseointegration in diabetes
Diabetes mellitus compromises bone regeneration and increases implant failure rates, posing persistent challenges in orthopedic and dental therapies. Although macrophage-centered immunomodulation has been widely investigated, the role of neutrophils, particularly under diabetic conditions, remains insufficiently defined. Here, we identify neutrophil dysfunction, characterized by impaired chemotaxis and elevated oxidative stress, as a critical upstream driver of impaired osseointegration in diabetes. We demonstrate that dietary flavonoid quercetin restores neutrophil redox homoeostasis in association with reactivation of Nrf2/HO-1 signaling, attenuates pathological neutrophil extracellular trap formation, and promotes MerTK-associated efferocytosis by macrophages. Efferocytosis of quercetin-treated neutrophils subsequently reprograms macrophage toward an anti-inflammatory, pro-regenerative M2-like phenotype, therefore establishing a microenvironment favorable for angiogenesis and osteogenesis. Based on these insights, we engineer a biodegradable tri-layered coating on polyetheretherketone (PEEK) implant, comprising an osteoconductive nano-hydroxyapatite base layer, a quercetin-rich antioxidant intermediate layer, and an outermost surface functionalized with the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) to actively recruit neutrophils. In a diabetic rat model, this rationally designed interface enables temporal coordination of innate immune responses, leading to substantially improved vascularized bone regeneration and implant osseointegration. These findings highlight neutrophils as key therapeutic targets in diabetic bone repair and propose an immunomodulatory biomaterials strategy that addresses upstream immune dysregulation in compromised metabolic conditions.
- 1 October 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 64, 641-654
Open AccessSpatiotemporal regulation of neutrophil-mediated immune cascades via engineered PEEK surfaces restores osseointegration in diabetes
Diabetes mellitus compromises bone regeneration and increases implant failure rates, posing persistent challenges in orthopedic and dental therapies. Although macrophage-centered immunomodulation has been widely investigated, the role of neutrophils, particularly under diabetic conditions, remains insufficiently defined. Here, we identify neutrophil dysfunction, characterized by impaired chemotaxis and elevated oxidative stress, as a critical upstream driver of impaired osseointegration in diabetes. We demonstrate that dietary flavonoid quercetin restores neutrophil redox homoeostasis in association with reactivation of Nrf2/HO-1 signaling, attenuates pathological neutrophil extracellular trap formation, and promotes MerTK-associated efferocytosis by macrophages. Efferocytosis of quercetin-treated neutrophils subsequently reprograms macrophage toward an anti-inflammatory, pro-regenerative M2-like phenotype, therefore establishing a microenvironment favorable for angiogenesis and osteogenesis. Based on these insights, we engineer a biodegradable tri-layered coating on polyetheretherketone (PEEK) implant, comprising an osteoconductive nano-hydroxyapatite base layer, a quercetin-rich antioxidant intermediate layer, and an outermost surface functionalized with the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) to actively recruit neutrophils. In a diabetic rat model, this rationally designed interface enables temporal coordination of innate immune responses, leading to substantially improved vascularized bone regeneration and implant osseointegration. These findings highlight neutrophils as key therapeutic targets in diabetic bone repair and propose an immunomodulatory biomaterials strategy that addresses upstream immune dysregulation in compromised metabolic conditions.
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1889301
Regulation of bone immunity by metal ions: a review of mechanisms and application progress
The formation and repair of bone tissue depend not only on the activity of bone tissue cells but also on complex regulatory mechanisms mediated by the immune system. With the advancements of osteoimmunology in recent years, the functional roles of metal ions in this field have attracted extensive attention. Various metal ions, including zinc, magnesium, manganese, strontium, and copper, are demonstrated to influence the osteoimmune microenvironment and promote bone repair by modulating the biological functions of immune cells, especially the inflammatory response. However, the precise mechanisms through which metal ions orchestrate osteoimmunity have not been fully elucidated, and the underlying signaling pathways, as well as their internal interactions with cells involved in bone repair, require further in-depth investigation. This review summarizes the regulatory effects of various metal ions on macrophages, T cells, dendritic cells, and neutrophils, including phenotype polarization, maturation, differentiation, inflammatory cytokine expression, and underlying signaling pathways. Besides, this review further discusses the application of metal ion-doped biomaterials in bone tissue engineering, while also covers their functions in remodeling the osteoimmune microenvironment and highlights potential directions for future research directions.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1889301
Open AccessRegulation of bone immunity by metal ions: a review of mechanisms and application progress
The formation and repair of bone tissue depend not only on the activity of bone tissue cells but also on complex regulatory mechanisms mediated by the immune system. With the advancements of osteoimmunology in recent years, the functional roles of metal ions in this field have attracted extensive attention. Various metal ions, including zinc, magnesium, manganese, strontium, and copper, are demonstrated to influence the osteoimmune microenvironment and promote bone repair by modulating the biological functions of immune cells, especially the inflammatory response. However, the precise mechanisms through which metal ions orchestrate osteoimmunity have not been fully elucidated, and the underlying signaling pathways, as well as their internal interactions with cells involved in bone repair, require further in-depth investigation. This review summarizes the regulatory effects of various metal ions on macrophages, T cells, dendritic cells, and neutrophils, including phenotype polarization, maturation, differentiation, inflammatory cytokine expression, and underlying signaling pathways. Besides, this review further discusses the application of metal ion-doped biomaterials in bone tissue engineering, while also covers their functions in remodeling the osteoimmune microenvironment and highlights potential directions for future research directions.
- Open Access
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7774
Publisher Correction: CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7774
Open AccessPublisher Correction: CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
- Open Access
- 8 May 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 58
Talin1 loss activates DRG neurons to accelerate bone remodeling and fracture healing in mice
- 8 May 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 58
Open AccessTalin1 loss activates DRG neurons to accelerate bone remodeling and fracture healing in mice
- Open Access
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
Osteocytes are long-lived with underlying mechanisms largely unknown. Here, we report that osteocyte-specific knockout of cystic fibrosis transmembrane conductance regulator (CFTR) results in excessive osteocyte death, proinflammatory cytokine surge, osteoclast overactivation and bone formation impairment leading to bone loss in adult mice. Consistently in MLO‑Y4 osteocyte‑line, CFTR-knockout causes progressive cell death, which is reversed by CFTR overexpression or medium replenishment. A massive proinflammatory osteocyte secretome is evoked by CFTR-knockout, which deteriorates wild-type osteocytes, inhibits osteogenic differentiation, while robustly stimulates osteoclastogenic differentiation in vitro. Patch-clamp/Cl--imaging verifies CFTR to mediate Cl- transport in osteocytes, while Cl--deprivation mimics CFTR-knockout to trigger transcriptomic/proteomic changes, cell stress and death. Additionally, osteocyte CFTR is downregulated in aged human bones; local delivery of CFTR via adenovirus or a CFTR modulator increases viable osteocytes and bone mass in aged mice. Together, the present study reveals a direct role of CFTR-mediated Cl- transport in sustaining osteocyte viability and skeletal homeostasis.
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
Osteocytes are long-lived with underlying mechanisms largely unknown. Here, we report that osteocyte-specific knockout of cystic fibrosis transmembrane conductance regulator (CFTR) results in excessive osteocyte death, proinflammatory cytokine surge, osteoclast overactivation and bone formation impairment leading to bone loss in adult mice. Consistently in MLO‑Y4 osteocyte‑line, CFTR-knockout causes progressive cell death, which is reversed by CFTR overexpression or medium replenishment. A massive proinflammatory osteocyte secretome is evoked by CFTR-knockout, which deteriorates wild-type osteocytes, inhibits osteogenic differentiation, while robustly stimulates osteoclastogenic differentiation in vitro. Patch-clamp/Cl--imaging verifies CFTR to mediate Cl- transport in osteocytes, while Cl--deprivation mimics CFTR-knockout to trigger transcriptomic/proteomic changes, cell stress and death. Additionally, osteocyte CFTR is downregulated in aged human bones; local delivery of CFTR via adenovirus or a CFTR modulator increases viable osteocytes and bone mass in aged mice. Together, the present study reveals a direct role of CFTR-mediated Cl- transport in sustaining osteocyte viability and skeletal homeostasis.
- Open Access
- 23 January 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1775689
Editorial: Osteocytes in bone health and beyond
With the advancement of modern technologies, the mysterious mechanisms underlying bone-our body's hardest tissue-have begun to be unveiled. Osteocytes, as the most abundant yet least well-studied cell type in bone, are attracting considerable attention due to their pivotal roles in maintaining bone health and systemic physiological homeostasis. Growing evidence demonstrates that osteocytes orchestrate bone formation and resorption, remodel the bone extracellular matrix, actively respond to physical stimuli, and function as endocrine cells to regulate distal organ physiology.This research topic encompasses six original articles that collectively illustrate the functional roles of osteocytes in the local regulation of bone microstructure, intercellular communication, and various pathological contexts. In this editorial, we summarize these contributions, highlight their key research findings and translational implications, and outline future directions in osteocyte biology.Highlight from the research topic Osteocyte death has long been linked to bone mass loss in various bone diseases. Zhao et al. summarized the mechanisms underlying different types of osteocyte death, including apoptosis, necrosis, necroptosis, ferroptosis, and pyroptosis. Despite their distinct regulatory mechanisms, various forms of osteocyte death promote osteoclast formation by either actively secreting pro-inflammatory and pro-osteoclastogenic cytokinessuch as tumor necrosis factor alpha (TNF-α) and receptor activator of nuclear factor-kappa B ligand (RANKL)or passively releasing pro-inflammatory damage-associated molecular patterns (DAMPs), such as high mobility group box 1 (HMGB1). Their work clarifies the potential mechanisms by which osteocyte death regulate osteoclast formation, aiming to improve the understanding of bone disease pathogenesis and identify potential therapeutic targets.Sclerostin (SOST) is a Wnt signaling inhibitor primarily secreted by osteocytes that regulates bone formation and homeostasis. Wu et al. revealed that in the db/db mouse model of type 2 diabetes mellitus (T2DM), sclerostin expression was elevated and accumulated within the cortical osteocyte lacunar-canalicular system (LCS). This accumulation was correlated with increased expression of matrix-degrading enzymes including Cathepsin K (CTSK) and matrix metalloproteinase 13 (MMP-13)in osteocytes. Furthermore, in vitro experiments using recombinant sclerostin confirmed that the local effects of sclerostin within the LCS contribute to bone matrix degradation. This study elucidates the underlying mechanism of bone fragility in T2DM-related bone disease and highlights sclerostin's local role during bone deterioration.Osteosarcoma (OS) is the most common primary malignant bone tumor, in which the dynamic crosstalk between malignant cells and the unique bone microenvironment is mediated by intricate immune cell interactions. Zhang et al. analyzed the paradoxical roles of immune cell subsets in OS pathophysiology and systematically evaluated recent advances in immune cell-targeted therapeutic strategies for OS, providing valuable insights to optimize immunotherapeutic approaches in OS management.Osteoarthritis (OA) is a major cause of lower limb mobility impairment in the elderly and the most prevalent joint disorder worldwide. Gao et al. summarized the current understanding of OA pathogenesis and symptom management. Jin et al. focused on the specific functions of E3 ubiquitin ligases (E3s) in OA pathogenesis: E3s influence OA progression by regulating the degradation of extracellular matrix proteins and inflammatory responses, thereby highlighting their roles and underlying mechanisms as potential targets for OA treatment. Another innovative OA therapeutic strategy is cartilage organoids, which are reported to target cartilage regeneration and structural repair. Gao et al. explored the development of cartilage organoids and discussed their future applications in drug screening and personalized therapies for OA.Finally, Wu et al. reviewed the latest advances in osteocyte biology, focusing on their mechanotransduction via Piezo1 and integrins, regulation of osteoclastogenesis and osteogenesis, and crosstalk with the bone marrow microenvironment-including immune cells and vascular cells. Their systematic review highlights the accelerating pace of osteocyte-related research and the development of osteocyte-targeted therapeutic strategies for preventing osteoporosis, improving bone strength, and enhancing bone regeneration.Collectively, these contributions demonstrate how osteocytes regulate the local bone microenvironment, communicate with other cell types within the bone, and contribute to key bone pathological processes such as osteoporosis, OS, and OA. By integrating molecular, cellular, and systems-level knowledge, we highlight osteocytes as a pivotal therapeutic target for combating bone diseases and promoting bone regeneration. Looking ahead, further progress will depend on emerging approaches-including organoids therapy, CRISPR-mediated gene editing, and AI-driven multi-omics for precision medicine-which are accelerating
- 23 January 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1775689
Open AccessEditorial: Osteocytes in bone health and beyond
With the advancement of modern technologies, the mysterious mechanisms underlying bone-our body's hardest tissue-have begun to be unveiled. Osteocytes, as the most abundant yet least well-studied cell type in bone, are attracting considerable attention due to their pivotal roles in maintaining bone health and systemic physiological homeostasis. Growing evidence demonstrates that osteocytes orchestrate bone formation and resorption, remodel the bone extracellular matrix, actively respond to physical stimuli, and function as endocrine cells to regulate distal organ physiology.This research topic encompasses six original articles that collectively illustrate the functional roles of osteocytes in the local regulation of bone microstructure, intercellular communication, and various pathological contexts. In this editorial, we summarize these contributions, highlight their key research findings and translational implications, and outline future directions in osteocyte biology.Highlight from the research topic Osteocyte death has long been linked to bone mass loss in various bone diseases. Zhao et al. summarized the mechanisms underlying different types of osteocyte death, including apoptosis, necrosis, necroptosis, ferroptosis, and pyroptosis. Despite their distinct regulatory mechanisms, various forms of osteocyte death promote osteoclast formation by either actively secreting pro-inflammatory and pro-osteoclastogenic cytokinessuch as tumor necrosis factor alpha (TNF-α) and receptor activator of nuclear factor-kappa B ligand (RANKL)or passively releasing pro-inflammatory damage-associated molecular patterns (DAMPs), such as high mobility group box 1 (HMGB1). Their work clarifies the potential mechanisms by which osteocyte death regulate osteoclast formation, aiming to improve the understanding of bone disease pathogenesis and identify potential therapeutic targets.Sclerostin (SOST) is a Wnt signaling inhibitor primarily secreted by osteocytes that regulates bone formation and homeostasis. Wu et al. revealed that in the db/db mouse model of type 2 diabetes mellitus (T2DM), sclerostin expression was elevated and accumulated within the cortical osteocyte lacunar-canalicular system (LCS). This accumulation was correlated with increased expression of matrix-degrading enzymes including Cathepsin K (CTSK) and matrix metalloproteinase 13 (MMP-13)in osteocytes. Furthermore, in vitro experiments using recombinant sclerostin confirmed that the local effects of sclerostin within the LCS contribute to bone matrix degradation. This study elucidates the underlying mechanism of bone fragility in T2DM-related bone disease and highlights sclerostin's local role during bone deterioration.Osteosarcoma (OS) is the most common primary malignant bone tumor, in which the dynamic crosstalk between malignant cells and the unique bone microenvironment is mediated by intricate immune cell interactions. Zhang et al. analyzed the paradoxical roles of immune cell subsets in OS pathophysiology and systematically evaluated recent advances in immune cell-targeted therapeutic strategies for OS, providing valuable insights to optimize immunotherapeutic approaches in OS management.Osteoarthritis (OA) is a major cause of lower limb mobility impairment in the elderly and the most prevalent joint disorder worldwide. Gao et al. summarized the current understanding of OA pathogenesis and symptom management. Jin et al. focused on the specific functions of E3 ubiquitin ligases (E3s) in OA pathogenesis: E3s influence OA progression by regulating the degradation of extracellular matrix proteins and inflammatory responses, thereby highlighting their roles and underlying mechanisms as potential targets for OA treatment. Another innovative OA therapeutic strategy is cartilage organoids, which are reported to target cartilage regeneration and structural repair. Gao et al. explored the development of cartilage organoids and discussed their future applications in drug screening and personalized therapies for OA.Finally, Wu et al. reviewed the latest advances in osteocyte biology, focusing on their mechanotransduction via Piezo1 and integrins, regulation of osteoclastogenesis and osteogenesis, and crosstalk with the bone marrow microenvironment-including immune cells and vascular cells. Their systematic review highlights the accelerating pace of osteocyte-related research and the development of osteocyte-targeted therapeutic strategies for preventing osteoporosis, improving bone strength, and enhancing bone regeneration.Collectively, these contributions demonstrate how osteocytes regulate the local bone microenvironment, communicate with other cell types within the bone, and contribute to key bone pathological processes such as osteoporosis, OS, and OA. By integrating molecular, cellular, and systems-level knowledge, we highlight osteocytes as a pivotal therapeutic target for combating bone diseases and promoting bone regeneration. Looking ahead, further progress will depend on emerging approaches-including organoids therapy, CRISPR-mediated gene editing, and AI-driven multi-omics for precision medicine-which are accelerating
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Naringin-based hydrogel decorated 3D printed scaffold modulates immunity and angiogenesis for diabetic bone regeneration
Hyperglycemia and inflammation within the diabetic microenvironment impair the healing of bone defects in diabetic patients. A key limitation of current therapeutic approaches is their lack of efficacy in restoring immune homeostasis. Herein, a novel 3D-printed PHSN composite scaffold is designed to regulate the immune microenvironment. PHSN is fabricated by integrating poly (lactic-co-glycolic acid) (PLGA) with hydroxyapatite (HA) via 3D printing technology, yielding a structure that combines osteogenic potential with mechanical strength. Loaded with naringin and SupGels, PHSN promotes macrophage repolarization toward the M2 phenotype via the JAK/STAT signaling pathway, thereby upregulating anti-inflammatory mediators and tissue-regeneration factors, stimulating angiogenesis and osteogenesis. In diabetic models, PHSN inhibits M1 macrophage polarization, drives reprogramming toward the M2 phenotype and upregulates the expression of CD31, ALP and OCN at bone defect sites, indicating enhanced angiogenesis and osteogenesis. Collectively, this study establishes a strategy of synergistically modulating immunity, vascularization and bone formation, offering a promising and translatable solution for diabetic bone regeneration.
- 22 January 2026
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 13
Open AccessNaringin-based hydrogel decorated 3D printed scaffold modulates immunity and angiogenesis for diabetic bone regeneration
Hyperglycemia and inflammation within the diabetic microenvironment impair the healing of bone defects in diabetic patients. A key limitation of current therapeutic approaches is their lack of efficacy in restoring immune homeostasis. Herein, a novel 3D-printed PHSN composite scaffold is designed to regulate the immune microenvironment. PHSN is fabricated by integrating poly (lactic-co-glycolic acid) (PLGA) with hydroxyapatite (HA) via 3D printing technology, yielding a structure that combines osteogenic potential with mechanical strength. Loaded with naringin and SupGels, PHSN promotes macrophage repolarization toward the M2 phenotype via the JAK/STAT signaling pathway, thereby upregulating anti-inflammatory mediators and tissue-regeneration factors, stimulating angiogenesis and osteogenesis. In diabetic models, PHSN inhibits M1 macrophage polarization, drives reprogramming toward the M2 phenotype and upregulates the expression of CD31, ALP and OCN at bone defect sites, indicating enhanced angiogenesis and osteogenesis. Collectively, this study establishes a strategy of synergistically modulating immunity, vascularization and bone formation, offering a promising and translatable solution for diabetic bone regeneration.
- Open Access
- 12 December 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1668766
Cartilage organoids: an emerging platform for novel osteoarthritis therapies
Osteoarthritis (OA) is a chronic, multifactorial joint disorder characterized by the progressive degeneration and dysfunction of various joint tissues. Current treatments primarily focus on symptom management, offering limited success in halting cartilage degradation or repairing damaged tissues. Consequently, there is a pressing need for innovative therapeutic strategies aimed at cartilage regeneration and structural repair. Over the past 2 decades, cartilage organoids have emerged as a promising alternative for OA treatment. Due to their unique regenerative properties, cartilage organoids provide a versatile platform for various applications in OA research and therapy, including in vitro disease modeling, drug screening, regenerative medicine, and biomechanical studies. This review summarizes current research progress and insights into OA pathogenesis and therapeutic approaches, explores the development of cartilage organoid technologies with a focus on organoid constructions and different methodologies, and discusses the future applications of cartilage organoids as essential in vitro models for drug screening and personalized therapies for OA studies and treatment.
- 12 December 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1668766
Open AccessCartilage organoids: an emerging platform for novel osteoarthritis therapies
Osteoarthritis (OA) is a chronic, multifactorial joint disorder characterized by the progressive degeneration and dysfunction of various joint tissues. Current treatments primarily focus on symptom management, offering limited success in halting cartilage degradation or repairing damaged tissues. Consequently, there is a pressing need for innovative therapeutic strategies aimed at cartilage regeneration and structural repair. Over the past 2 decades, cartilage organoids have emerged as a promising alternative for OA treatment. Due to their unique regenerative properties, cartilage organoids provide a versatile platform for various applications in OA research and therapy, including in vitro disease modeling, drug screening, regenerative medicine, and biomechanical studies. This review summarizes current research progress and insights into OA pathogenesis and therapeutic approaches, explores the development of cartilage organoid technologies with a focus on organoid constructions and different methodologies, and discusses the future applications of cartilage organoids as essential in vitro models for drug screening and personalized therapies for OA studies and treatment.
- 2 December 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (2) , 941-962
FGF2 Enhances MSCs Secretome Therapy for Skin Photoaging by Delaying Senescence via iNAMPT/AMPK Signaling and Facilitating eNAMPT-Mediated Regenerative Crosstalk
- 2 December 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (2) , 941-962
FGF2 Enhances MSCs Secretome Therapy for Skin Photoaging by Delaying Senescence via iNAMPT/AMPK Signaling and Facilitating eNAMPT-Mediated Regenerative Crosstalk
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (5)
Establishment and characterization of a human pre-osteocyte cell line: hOsteo4-E9
Osteocytes, as the most abundant and long-lived cell type in bone tissue, have garnered significant attention due to their critical roles in bone remodeling, bone mechanobiology, bone-related diseases, and systemic homeostasis. While several well-established murine osteocyte cell lines are available, the development of a reliable human-derived osteocyte cell line remains an unmet need in the field. Here, we report the successful purification of primary bone cells from the adult human lumbar articular process and their immortalization via SV40 antigen transduction. The resulting human cell line, designated hOsteo4, exhibits high expression of early osteocyte markers (E11, DMP1), moderate levels of ALP and COL1, and low expression of late osteocyte markers (sclerostin, FGF23). Quantitative PCR analysis and in vitro osteoblastic differentiation assays indicate that hOsteo4 cells represent pre-osteocytes at the transitional stage from late osteoblasts to osteocytes. Notably, the subclone hOsteo4-E9 demonstrates robust responsiveness to fluid shear stress (FSS), characterized by dramatic morphological remodeling and upregulated focal adhesion protein expression. RNA-sequencing further reveals distinct FSS-responsive gene expression profiles when comparing human hOsteo4-E9 to the murine MLO-Y4 cell line. Collectively, hOsteo4-E9, a novel immortalized human pre-osteocyte-like cell line, represents an invaluable experimental tool that promises to advance mechanistic insights into human osteocyte biology.
- 17 October 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (5)
Open AccessEstablishment and characterization of a human pre-osteocyte cell line: hOsteo4-E9
Osteocytes, as the most abundant and long-lived cell type in bone tissue, have garnered significant attention due to their critical roles in bone remodeling, bone mechanobiology, bone-related diseases, and systemic homeostasis. While several well-established murine osteocyte cell lines are available, the development of a reliable human-derived osteocyte cell line remains an unmet need in the field. Here, we report the successful purification of primary bone cells from the adult human lumbar articular process and their immortalization via SV40 antigen transduction. The resulting human cell line, designated hOsteo4, exhibits high expression of early osteocyte markers (E11, DMP1), moderate levels of ALP and COL1, and low expression of late osteocyte markers (sclerostin, FGF23). Quantitative PCR analysis and in vitro osteoblastic differentiation assays indicate that hOsteo4 cells represent pre-osteocytes at the transitional stage from late osteoblasts to osteocytes. Notably, the subclone hOsteo4-E9 demonstrates robust responsiveness to fluid shear stress (FSS), characterized by dramatic morphological remodeling and upregulated focal adhesion protein expression. RNA-sequencing further reveals distinct FSS-responsive gene expression profiles when comparing human hOsteo4-E9 to the murine MLO-Y4 cell line. Collectively, hOsteo4-E9, a novel immortalized human pre-osteocyte-like cell line, represents an invaluable experimental tool that promises to advance mechanistic insights into human osteocyte biology.